Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombolytic Therapy | 6 | 2025 | 252 | 1.630 |
Why?
|
| Pulmonary Embolism | 4 | 2022 | 232 | 1.260 |
Why?
|
| Cardiac Tamponade | 2 | 2018 | 23 | 1.170 |
Why?
|
| Thrombosis | 6 | 2021 | 313 | 0.810 |
Why?
|
| Haemophilus influenzae | 2 | 2018 | 17 | 0.750 |
Why?
|
| Haemophilus Infections | 1 | 2018 | 8 | 0.580 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 20 | 0.570 |
Why?
|
| Leiomyosarcoma | 1 | 2018 | 46 | 0.550 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 229 | 0.550 |
Why?
|
| Catheterization, Central Venous | 1 | 2018 | 114 | 0.530 |
Why?
|
| Renal Veins | 1 | 2017 | 29 | 0.530 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 33 | 0.520 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 140 | 0.520 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 86 | 0.490 |
Why?
|
| Catheterization | 1 | 2017 | 237 | 0.480 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2022 | 174 | 0.470 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 379 | 0.430 |
Why?
|
| Anticoagulants | 3 | 2021 | 448 | 0.420 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 145 | 0.400 |
Why?
|
| Recycling | 1 | 2012 | 3 | 0.400 |
Why?
|
| Water Purification | 1 | 2012 | 4 | 0.400 |
Why?
|
| Waste Disposal, Fluid | 1 | 2012 | 3 | 0.400 |
Why?
|
| Filtration | 1 | 2012 | 26 | 0.390 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 298 | 0.390 |
Why?
|
| Ultrasonic Therapy | 2 | 2025 | 42 | 0.380 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 291 | 0.380 |
Why?
|
| Venous Thrombosis | 3 | 2025 | 254 | 0.380 |
Why?
|
| Fibrinolytic Agents | 4 | 2022 | 233 | 0.380 |
Why?
|
| Tissue Engineering | 1 | 2013 | 198 | 0.370 |
Why?
|
| Water Pollutants, Chemical | 1 | 2012 | 139 | 0.350 |
Why?
|
| Heparin | 2 | 2021 | 185 | 0.340 |
Why?
|
| Cardiac Catheterization | 5 | 2016 | 324 | 0.320 |
Why?
|
| Shock, Cardiogenic | 4 | 2016 | 133 | 0.320 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 2 | 2021 | 46 | 0.320 |
Why?
|
| Heart-Assist Devices | 5 | 2016 | 864 | 0.300 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1241 | 0.270 |
Why?
|
| Biomarkers | 4 | 2021 | 1847 | 0.260 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2013 | 143 | 0.260 |
Why?
|
| Exercise Therapy | 1 | 2007 | 88 | 0.260 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 433 | 0.240 |
Why?
|
| Nitric Oxide | 1 | 2007 | 280 | 0.240 |
Why?
|
| Femoral Vein | 1 | 2025 | 42 | 0.230 |
Why?
|
| Stem Cells | 1 | 2007 | 382 | 0.220 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2019 | 205 | 0.220 |
Why?
|
| Humans | 28 | 2022 | 92339 | 0.220 |
Why?
|
| Aortic Valve | 2 | 2017 | 260 | 0.200 |
Why?
|
| Phantoms, Imaging | 3 | 2021 | 474 | 0.200 |
Why?
|
| Fibrinolysis | 1 | 2022 | 37 | 0.190 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 56 | 0.180 |
Why?
|
| Echocardiography, Transesophageal | 5 | 2016 | 358 | 0.170 |
Why?
|
| Embolectomy | 1 | 2020 | 7 | 0.170 |
Why?
|
| Antithrombins | 1 | 2020 | 17 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 91 | 0.170 |
Why?
|
| Middle Aged | 16 | 2021 | 27043 | 0.170 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2017 | 522 | 0.170 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 47 | 0.160 |
Why?
|
| Female | 16 | 2021 | 47893 | 0.160 |
Why?
|
| Europe | 1 | 2020 | 328 | 0.160 |
Why?
|
| Elastic Modulus | 1 | 2019 | 38 | 0.160 |
Why?
|
| Gels | 1 | 2019 | 52 | 0.160 |
Why?
|
| Aged | 12 | 2021 | 19951 | 0.160 |
Why?
|
| Lithotripsy | 1 | 2019 | 45 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2020 | 234 | 0.160 |
Why?
|
| Microbubbles | 1 | 2019 | 40 | 0.160 |
Why?
|
| Recurrence | 2 | 2020 | 1180 | 0.160 |
Why?
|
| Cardiology | 1 | 2020 | 122 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2021 | 707 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2022 | 8730 | 0.150 |
Why?
|
| Administration, Oral | 1 | 2020 | 672 | 0.150 |
Why?
|
| Acute Disease | 1 | 2020 | 855 | 0.150 |
Why?
|
| Pericardiocentesis | 1 | 2018 | 6 | 0.150 |
Why?
|
| Pericarditis | 1 | 2018 | 16 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 223 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2019 | 114 | 0.140 |
Why?
|
| Binge Drinking | 1 | 2018 | 15 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 165 | 0.140 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 94 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2018 | 299 | 0.140 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2015 | 71 | 0.130 |
Why?
|
| Phlebography | 1 | 2017 | 65 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2020 | 2368 | 0.130 |
Why?
|
| Male | 16 | 2021 | 43927 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2020 | 596 | 0.130 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 64 | 0.130 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 223 | 0.120 |
Why?
|
| Disease Progression | 1 | 2020 | 1505 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1761 | 0.120 |
Why?
|
| Macrophages | 1 | 2019 | 601 | 0.120 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 30 | 0.120 |
Why?
|
| Heart Failure | 3 | 2016 | 1341 | 0.120 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 157 | 0.120 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 245 | 0.110 |
Why?
|
| Pericytes | 1 | 2013 | 14 | 0.110 |
Why?
|
| Adult | 8 | 2022 | 27538 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2016 | 308 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 250 | 0.100 |
Why?
|
| Calcium Carbonate | 1 | 2012 | 4 | 0.100 |
Why?
|
| Software | 1 | 2017 | 676 | 0.100 |
Why?
|
| Water Movements | 1 | 2012 | 8 | 0.100 |
Why?
|
| London | 1 | 2012 | 17 | 0.100 |
Why?
|
| Water Pollution | 1 | 2012 | 9 | 0.100 |
Why?
|
| Cell Communication | 1 | 2013 | 206 | 0.100 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2013 | 70 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 376 | 0.100 |
Why?
|
| Metals, Heavy | 1 | 2012 | 16 | 0.100 |
Why?
|
| Balloon Occlusion | 1 | 2012 | 30 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2016 | 284 | 0.100 |
Why?
|
| RNA Interference | 1 | 2013 | 385 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2685 | 0.100 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 124 | 0.100 |
Why?
|
| Water Supply | 1 | 2012 | 62 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 808 | 0.100 |
Why?
|
| Endothelial Cells | 2 | 2013 | 472 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 693 | 0.100 |
Why?
|
| Catheters | 2 | 2022 | 86 | 0.090 |
Why?
|
| Models, Chemical | 1 | 2012 | 181 | 0.090 |
Why?
|
| Swine | 2 | 2025 | 607 | 0.090 |
Why?
|
| Cell Movement | 1 | 2013 | 801 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2021 | 289 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 670 | 0.080 |
Why?
|
| In Vitro Techniques | 2 | 2022 | 998 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2013 | 757 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2021 | 444 | 0.070 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 639 | 0.070 |
Why?
|
| Septal Occluder Device | 3 | 2013 | 51 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1480 | 0.070 |
Why?
|
| Nitrites | 1 | 2007 | 33 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 35 | 0.070 |
Why?
|
| Phenotype | 1 | 2013 | 2502 | 0.070 |
Why?
|
| Exercise Test | 1 | 2007 | 172 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 237 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 112 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2007 | 236 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2021 | 1511 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 708 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2025 | 40 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 899 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2004 | 51 | 0.060 |
Why?
|
| Critical Illness | 2 | 2021 | 327 | 0.060 |
Why?
|
| Fluoroscopy | 1 | 2025 | 129 | 0.060 |
Why?
|
| Animals | 4 | 2025 | 28053 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 3776 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 488 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2004 | 167 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2022 | 1016 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2004 | 233 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 262 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 391 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 3509 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 322 | 0.050 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2013 | 106 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2019 | 474 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6920 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2021 | 31 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 131 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2022 | 149 | 0.050 |
Why?
|
| Mice | 2 | 2013 | 12136 | 0.050 |
Why?
|
| Prosthesis Design | 2 | 2013 | 302 | 0.040 |
Why?
|
| Peptides | 1 | 2004 | 656 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2022 | 190 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2022 | 9689 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2022 | 251 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 288 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 244 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 694 | 0.040 |
Why?
|
| Acoustics | 1 | 2019 | 52 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 391 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 379 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 153 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 2449 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1239 | 0.030 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 786 | 0.030 |
Why?
|
| Time Factors | 1 | 2025 | 5429 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1733 | 0.030 |
Why?
|
| Cannula | 1 | 2016 | 56 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 123 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 290 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 790 | 0.030 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2015 | 82 | 0.030 |
Why?
|
| Heart Atria | 1 | 2016 | 289 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 903 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 562 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1270 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 52 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2009 | 0.020 |
Why?
|
| United States | 2 | 2016 | 7348 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 121 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 886 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2793 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 653 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1960 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1463 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1920 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2004 | 10 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2004 | 41 | 0.010 |
Why?
|
| Filgrastim | 1 | 2004 | 58 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 80 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 48 | 0.010 |
Why?
|
| Risk Factors | 2 | 2005 | 5706 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 161 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 310 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2905 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1607 | 0.010 |
Why?
|